Étiquette : MDMA

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, Edward James et al., 2019

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C  -  ISSN 1756-8919   “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy   The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]

Lire la suite

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, Edward James et al., 2019

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447   Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]

Lire la suite

The Prosocial Effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled Studies in Humans and Laboratory Animals, Philip Kamilar-Britt and Gillinder Bedi, 2015

The Prosocial Effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled Studies in Humans and Laboratory Animals Philip Kamilar-Britt and Gillinder Bedi Neuroscience & Biobehavioral Reviews, 2015, 57, 433–446. doi:10.1016/j.neubiorev.2015.08.016   Abstract Users of ±3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) report prosocial effects such as sociability and empathy. Supporting these apparently unique social effects, data from controlled laboratory studies indicate that MDMA alters social feelings, information processing, and behavior in humans, and social behavior in rodents. Here, we review this growing body of evidence. In rodents, MDMA increases passive prosocial behavior (adjacent lying) and social reward while decreasing aggression, effects that may involve serotonin 1A receptor mediated oxytocin release interacting with vasopressin receptor [...]

Lire la suite

Why Psychiatry Needs 3,4 Methylenedioxymethamphetamine : A Child Psychiatrist’s Perspective, Ben SESSA, 2017

Why Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]

Lire la suite

Hallucinogens and Their Therapeutic Use : A Literature Review, Matthew J. BEGOLA, Jason E. SCHILLERSTROM,2019

Hallucinogens and Their Therapeutic Use : A Literature Review Matthew J. BEGOLA, Jason E. SCHILLERSTROM Journal of Psychiatric Practice, 2019, 25, (5), 334–346 Doi : 10.1097/PRA.0000000000000409   The exploration of possible therapeutic benefitsof hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. [...]

Lire la suite

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity, Robin L. Carhart-Harris et al., 2015

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity Robin L. Carhart-Harris, Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, Leor Roseman, Stefan Brugger, Ineke De Meer, Mark Tanner, Robin Tyacke, Kim Wolff, Ajun Sethi, Michael A.P. Bloomfield, Tim M. Williams, Mark Bolstridge, Lorna Stewart, Celia Morgan, Rexford D. Newbould, Amanda Feilding, H. Val Curran, and David J. Nutt Biological Psychiatry, 2015, 78, 554-562. http://dx.doi.org/10.1016/j.biopsych.2013.12.015   ABSTRACT BACKGROUND : The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals. METHODS : [...]

Lire la suite

Receptor-Enriched Analysis of functional connectivity by targets (REACT) : A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA, Ottavia Dipasquale et al., 2019

Receptor-Enriched Analysis of functional connectivity by targets (REACT) : A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese, Anthony S. Gabay, Federico Turkheimer, Mitul A. Mehta NeuroImage, 2019, 195, 252–260 https://doi.org/10.1016/j.neuroimage.2019.04.007   A B S T R A C T One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylene-dioxymethamphetamine (MDMA) on functional [...]

Lire la suite

The Role of MDMA Neurotoxicity in Anxiety, Casey R. Guillot et al., 2007

The Role of MDMA Neurotoxicity in Anxiety Casey R. Guillot, Mitchell E. Berman and Brenton R. Abadie In : Neurotoxicity Syndromes, Chapter I ISBN: 978-1-60021-797-5 Editor: Linda R. Webster, pp. 1 - 36 © 2007 Nova Science Publishers, Inc. Abstract The drug 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) long has been considered a neurotoxin selective for serotonin (5-hydroxytryptamine; 5-HT) axons in rats and nonhuman primates. MDMA is also thought to have the potential to cause persistent serotonergic alterations in humans. Since the serotonin system is involved in the regulation of anxiety, researchers have proposed that recreational Ecstasy users may be at risk for the development of anxiety disorders and symptoms. [...]

Lire la suite

Psychedelics, David E. Nichols, 2016

Psychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478   Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]

Lire la suite